Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
131
NCT01386580
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 31, 2011
Completion: Dec 31, 2014
NCT02048358
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
Phase: Phase 1
Start: Nov 30, 2013
Completion: Feb 28, 2015